Skip to main content

Treatment Clinical Trials for Malignant Head and Neck Neoplasm

Review the malignant head and neck neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 262

Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer
Status: Active
Location: 512 locations
Study of Targeted Therapy vs. Chemotherapy in Patients with Thyroid Cancer
Status: Active
Location: 291 locations
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients with Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Status: Active
Location: 220 locations
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer after Previous Treatment
Status: Active
Location: 195 locations
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People with Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
Status: Active
Location: 146 locations
Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 145 locations
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 145 locations
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Status: Active
Location: 113 locations
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Status: Active
Location: 103 locations
A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Status: Active
Location: 77 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 81 locations
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Status: Active
Location: 33 locations
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Status: Active
Location: 30 locations
Use of Lymphatic Mapping to Guide Radiotherapy to the Neck in Oropharyngeal Cancer
Status: Active
Location: 25 locations
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Status: Active
Location: 24 locations
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 21 locations
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Status: Active
Location: 21 locations
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients with Sinonasal Squamous Cell Carcinoma
Status: Active
Location: 18 locations
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Status: Active
Location: 18 locations
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Status: Active
Location: 15 locations
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Status: Active
Location: 20 locations
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Status: Active
Location: 15 locations
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Status: Active
Location: 14 locations
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Status: Active
Location: 16 locations